Year All20242023202220212020201920182017201620152014 Abivax phase 2b study results of obefazimod (ABX464) in ulcerative colitis published in the Lancet Gastroenterology & Hepatology September 06, 2022 Read More Abivax publishes a prospectus in the context of its capital increase September 02, 2022 Read More Abivax announces successful oversubscribed EUR 49.2M cross-over financing with top-tier US and European Biotech investors September 02, 2022 Read More Abivax announces a change in its governance August 16, 2022 Read More Abivax phase 3 program with obefazimod in ulcerative colitis progresses with US IRB approval August 04, 2022 Read More Abivax releases the results of its June 9, 2022 ordinary annual and extraordinary general meeting June 10, 2022 Read More Abivax phase 2a study results of obefazimod (ABX464) in rheumatoid arthritis published in the journal “Annals of the Rheumatic Diseases” and selected for presentation at EULAR 2022 June 01, 2022 Read More Abivax announces annual ordinary and extraordinary general meeting on June 9, 2022, and the availability of the preparatory documents May 18, 2022 Read More Abivax publishes Universal Registration Document 2022 “Document d’Enregistrement Universel” April 28, 2022 Read More Abivax reports excellent one-year efficacy and safety data of ABX464 phase 2b maintenance trial in ulcerative colitis April 06, 2022 Read More
Abivax phase 2b study results of obefazimod (ABX464) in ulcerative colitis published in the Lancet Gastroenterology & Hepatology September 06, 2022 Read More
Abivax announces successful oversubscribed EUR 49.2M cross-over financing with top-tier US and European Biotech investors September 02, 2022 Read More
Abivax phase 3 program with obefazimod in ulcerative colitis progresses with US IRB approval August 04, 2022 Read More
Abivax releases the results of its June 9, 2022 ordinary annual and extraordinary general meeting June 10, 2022 Read More
Abivax phase 2a study results of obefazimod (ABX464) in rheumatoid arthritis published in the journal “Annals of the Rheumatic Diseases” and selected for presentation at EULAR 2022 June 01, 2022 Read More
Abivax announces annual ordinary and extraordinary general meeting on June 9, 2022, and the availability of the preparatory documents May 18, 2022 Read More
Abivax publishes Universal Registration Document 2022 “Document d’Enregistrement Universel” April 28, 2022 Read More
Abivax reports excellent one-year efficacy and safety data of ABX464 phase 2b maintenance trial in ulcerative colitis April 06, 2022 Read More
